MoonLake Immunotherapeutics (MLTX) Misses Q1 EPS by 2c

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q1 EPS of ($0.22), $0.02 worse than the analyst estimate of ($0.20). .

For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Deutsche Bank monitors UK auto sales as Chinese exports grow
• Beike (BEKE) PT Raised to $23 at Morgan Stanley